Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270122 | 0.90 | AXL (0.46) | AURKAAXLCDK2SYKBRD4 | |
| Hydrochloric Acid SCHEMBL266775 | 0.89 | AXL (0.46) | AURKAAXLCDK2SYKBRD4 | |
| SCHEMBL271260 | 0.88 | SCN9A (0.52) | AURKAAXLCDK2SYKBRD4 | |
| SCHEMBL12109393 | 0.85 | AXL (0.44) | AURKAAXLCDK2SYKBRD4 | |
| SCHEMBL12109284 | 0.85 | AXL (0.46) | AURKAAXLSYKROCK2WEE1 | |
| SCHEMBL271520 | 0.84 | AURKA (0.51) | AURKACDK2SYKBRD4CDK4 | |
| SCHEMBL271021 | 0.83 | SYK (0.68) | AURKAAXLCDK2SYKBRD4 | |
| SCHEMBL271306 | 0.81 | JAK2 (0.56) | AURKASYKBRD4JAK1HDAC1 | |
| SCHEMBL270995 | 0.81 | BRD4 (0.61) | AURKAAXLCDK2SYKBRD4 | |
| SCHEMBL270949 | 0.80 | BRD4 (0.49) | AURKAAXLSYKBRD4STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | AURKA 75/4885AXL 267/4885CDK2 14/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | AURKA 3934/4885AXL 2199/4885CDK2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.